Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality
Authors:
Open Access
- 6 May 2021
- journal article
- editorial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (11) , 2116-2118
Abstract
Recent randomized trials suggest that interleukin-6 inhibitors reduce mortality due to severe coronavirus disease 2019. Using a decision tree model, we found that tocilizumab is cost-effective with an estimated incremental cost-effectiveness ratio of $16 520 per quality-adjusted life year gained (95% credible interval, 10 760–51 530).Keywords
Funding Information
- National Institutes of Health (R01DA046527, P30DA040500, 5T32AI052074–13)
This publication has 8 references indexed in Scilit:
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialThe Lancet, 2021
- Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory SoupNew England Journal of Medicine, 2021
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19New England Journal of Medicine, 2021
- Tocilizumab in Patients Hospitalized with Covid-19 PneumoniaNew England Journal of Medicine, 2021
- Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased dischargeInternational Journal of Infectious Diseases, 2020
- Clinical Characteristics of Covid-19 in New York CityNew England Journal of Medicine, 2020
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness AnalysesJAMA, 2016
- Skills of the Trade: The Tufts Cost-Effectiveness Analysis RegistryJournal of Benefit-Cost Analysis, 2012